Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qnexa May Get Staged Launch After No Vote From Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Safety concerns and a large market potential for Vivus's obesity drug combine to produce an advisory panel recommendation that leaves FDA "a little surprised."
Advertisement

Related Content

Qnexa’s Second Advisory Committee Review: Smaller Indication, Still Big Safety Questions
Vivus Resubmits Qnexa, But Limits Its Market Opportunity
Vivus Resubmits Qnexa, But Limits Its Market Opportunity
Complaints To CDER Down, But Lorcaserin Weighs Heavily At Ombudsman's Office
Complaints To CDER Down, But Lorcaserin Weighs Heavily At Ombudsman's Office
Positive Two-Year Data Boost Prospects For Vivus' Qnexa
Positive Two-Year Data Boost Prospects For Vivus' Qnexa
Lorqess' Slight Efficacy, Potential Safety Issues Leave Arena On The Hot Seat At Advisory Panel
Qnexa Proposed REMS Focuses On Registry, Web-Based Physician Education
Qnexa Proposed REMS Focuses On Registry, Web-Based Physician Education

Topics

Advertisement
UsernamePublicRestriction

Register

PS070902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel